Tweet
http://phx.corporate-ir.net/phoenix....091&highlight=
The company plans to use the net proceeds from this proposed offering to support and fund several clinical trials, including a proposed Phase 2 clinical trial of its product candidate RGN-352 for the treatment of patients with acute myocardial infarction, an ongoing Phase 2 clinical trial of its product candidate RGN-137 in patients with the skin defect epidermolysis bullosa, compassionate use studies of its product candidate RGN-259 in patients with neurotrophic keratitis and a proposed physician-sponsored trial in patients with dry eye associated with graft versus host disease, as well as a proposed Phase 1/2 trial of RGN-352 in patients with multiple sclerosis. The company also plans to use the net proceeds for general corporate purposes, including working capital.
RDAC
The company plans to use the net proceeds from this proposed offering to support and fund several clinical trials, including a proposed Phase 2 clinical trial of its product candidate RGN-352 for the treatment of patients with acute myocardial infarction, an ongoing Phase 2 clinical trial of its product candidate RGN-137 in patients with the skin defect epidermolysis bullosa, compassionate use studies of its product candidate RGN-259 in patients with neurotrophic keratitis and a proposed physician-sponsored trial in patients with dry eye associated with graft versus host disease, as well as a proposed Phase 1/2 trial of RGN-352 in patients with multiple sclerosis. The company also plans to use the net proceeds for general corporate purposes, including working capital.
RDAC